# ATEMPT 2.0

Source: https://onco.cc/trials/nct04893109/  
OnCo record `nct04893109` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ATEMPT 2.0 compares a shorter course of T-DM1 followed by trastuzumab with paclitaxel and trastuzumab after breast surgery, tracking side effects and cancer recurrence.

## Summary

ATEMPT 2.0 compares a shorter course of T-DM1 followed by trastuzumab with paclitaxel and trastuzumab after breast surgery, tracking side effects and cancer recurrence.

Interventional study registered as NCT04893109, sponsored by Dana-Farber Cancer Institute. Registry phase: 2. Registry enrollment is 500 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Also known as: ATEMPT 2.0: Adjuvant T-DM1 vs TH
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT04893109
- Phase: 2
- Setting: HER2-positive breast cancer after surgery
- Sponsor: Dana-Farber Cancer Institute

## Sources

- ClinicalTrials.gov NCT04893109: https://clinicaltrials.gov/study/NCT04893109
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT04893109

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct04893109.json